Bath & Body Works, Inc.
—- Market cap
- —
- Debt
- +$3.89B
- Cash
- −$953.00M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BBWI stock price vs PACB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PACB's multiple
Needs PACB P/E.
Implied fair value · at BBWI's multiple
Needs Annual EPS is negative, BBWI P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BATH & BODY WORKS, INC. · implied price per share
Bear
$26.50
Base
$31.55
Bull
$40.51
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Victoria's Secret & Co.
BBWI vs VSCO
ABERCROMBIE & FITCH CO /DE/
BBWI vs ANF
ESTEE LAUDER COMPANIES INC
BBWI vs EL
Ulta Beauty, Inc.
BBWI vs ULTA
Sally Beauty Holdings, Inc.
BBWI vs SBH
ILLUMINA, INC.
BBWI vs ILMN
THERMO FISHER SCIENTIFIC INC.
BBWI vs TMO
AGILENT TECHNOLOGIES, INC.
BBWI vs A
DANAHER CORP /DE/
BBWI vs DHR
REVVITY, INC.
BBWI vs RVTY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BBWI can sustain its current profitability and avoid a sharp multiple re-rating lower, then BBWI looks attractive versus the PACB-based PACB valuation because BBWI already converts revenue into meaningful earnings while PACB does not.
BBWI trades at a large discount to PACB-implied valuation, with the P/S-based implied price of $118.22 versus a current price of $21.96. The gap is driven by the fact that BBWI generates much larger, profitable revenue, while PACB is loss-making and heavily leveraged, making a direct PACB multiple translation economically distorted.
Supporting Metrics